.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Optimizing Treatment Selection in Liver Cancer

EP. 1: Multidisciplinary Approaches in HCC

February 15th 2017

EP. 2: Liver Transplant Candidacy in HCC

February 15th 2017

EP. 3: Resection vs Transplant in HCC: Factors to Consider

February 15th 2017

EP. 4: Radiofrequency Ablation and Curative Intent in HCC

February 15th 2017

EP. 5: Locoregional Therapy Options in HCC

February 15th 2017

EP. 6: HCC: Timing of Locoregional and Systemic Therapies

February 15th 2017

EP. 7: Dosing Strategies With Sorafenib in HCC

February 15th 2017

EP. 8: Improving Survival in HCC

February 15th 2017

EP. 9: Incorporating Regorafenib in the HCC Treatment Landscape

February 15th 2017

EP. 10: Underlying Cirrhosis in the Second-Line Setting of HCC

February 15th 2017

EP. 11: Current Understanding With Biomarkers in HCC

February 15th 2017

EP. 12: Emerging c-MET Inhibitors in HCC

February 15th 2017

EP. 13: Emerging Multikinase Inhibitors in HCC

February 15th 2017

EP. 14: Evidence With Checkpoint Inhibition in HCC

February 15th 2017

EP. 15: The Future of HCC Treatment

February 15th 2017